BKYI earnings analysis
What we found in BKYI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q text is limited primarily to controls, legal proceedings, and other-information disclosures and does not include the current-quarter financial statements or MD&A needed to assess revenue, margins, EPS, cash flow, or segment performance. Controls were deemed effective as of June 30, 2026, and no material internal-control changes were reported for the quarter. No quantitative guidance was provided, while the filing did not include a separate Item 1A risk-factor update.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure Controls Remained Effective
- Management evaluated disclosure controls as of June 30, 2026 and concluded that the CEO and CFO considered them effective at a reasonable assurance level.
- No Material Control Changes
- The company reported that there were no changes during the quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No Updated Risk-Factor Disclosure
- Item 1A states that, as a smaller reporting company, BIO-key is not required to provide a separate risk-factor update in this filing. Investors are instead directed to the risks in the 2025 Form 10-K/A and other SEC disclosures.
- Limited Financial Trend Disclosure
- The extracted filing does not provide current-quarter revenue, EPS, cash-flow, balance-sheet, or segment figures, preventing confirmation of operating trends as of June 30, 2026.
What they said about what is next.
No quantitative outlook or explicit guidance was provided in the extracted 10-Q text; the filing directs investors to the 2025 Form 10-K/A and other SEC disclosures.
The filing reads about the same as the one before it.
What came before.
- 10-Q · June 22, 2026
- BIO-key International, Inc. reported its Q1 2026 results, revealing a revenue increase of 34% year-over-year to $2.14 million, primarily driven by a 24% rise in license fees and a 125% boost in hardware sales. Despite…
- 10-K · June 12, 2026
- BIO-key International, Inc. reported significant challenges in 2025, marked by a revenue decline of 14% year-over-year, leading to a net loss increasing to $7.16 million compared to $4.30 million in 2024. Strategic…
- 10-K · June 12, 2026
- BIO-key International, Inc. reported a challenging year with decreasing revenues and increased net losses. Despite a strategic focus on expanding its identity access management solutions, the company faced substantial…
- 10-Q · August 13, 2025
- BIO-key reported Q2 2025 revenue of $1,696,907, up 49% year-over-year driven by hardware (+581% to $568,824) and modest license growth (+4% to $806,087). Gross margin contracted to 73% (from 77% a year ago) and the…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BKYI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever